These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 10632320

  • 1. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G.
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [Abstract] [Full Text] [Related]

  • 2. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
    Loibl S, Königs A, Kaufmann M, Costa SD, Bischoff J.
    Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
    [Abstract] [Full Text] [Related]

  • 3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Dec; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 4. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
    Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H, Ziegler R, Seibel MJ.
    Br J Cancer; 2001 Feb 02; 84(3):344-51. PubMed ID: 11161399
    [Abstract] [Full Text] [Related]

  • 5. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers.
    Waltregny D, Bellahcène A, de Leval X, Florkin B, Weidle U, Castronovo V.
    J Bone Miner Res; 2000 May 02; 15(5):834-43. PubMed ID: 10804012
    [Abstract] [Full Text] [Related]

  • 6. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development.
    Bellahcene A, Kroll M, Liebens F, Castronovo V.
    J Bone Miner Res; 1996 May 02; 11(5):665-70. PubMed ID: 9157781
    [Abstract] [Full Text] [Related]

  • 7. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
    Jukkola A, Bloigu R, Holli K, Joensuu H, Valavaara R, Risteli J, Blanco G.
    Anticancer Res; 2001 May 02; 21(4B):2873-6. PubMed ID: 11712779
    [Abstract] [Full Text] [Related]

  • 8. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH, Zhao JH, Gong JP, Qin JW, Pan LQ, Xu ZY.
    Zhonghua Zhong Liu Za Zhi; 2007 Mar 02; 29(3):210-4. PubMed ID: 17649639
    [Abstract] [Full Text] [Related]

  • 9. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R, Classen S, Wolf H, Gholam P, Possinger K, Wilmanns W.
    Anticancer Res; 2001 Mar 02; 21(4B):2995-3000. PubMed ID: 11712800
    [Abstract] [Full Text] [Related]

  • 10. Serum tumor markers in skeletal metastasis.
    Tsukushi S, Katagiri H, Kataoka T, Nishida Y, Ishiguro N.
    Jpn J Clin Oncol; 2006 Jul 02; 36(7):439-44. PubMed ID: 16815865
    [Abstract] [Full Text] [Related]

  • 11. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
    Martinetti A, Bajetta E, Ferrari L, Zilembo N, Seregni E, Del Vecchio M, Longarini R, La Torre I, Toffolatti L, Paleari D, Bombardieri E.
    Endocr Relat Cancer; 2004 Dec 02; 11(4):771-9. PubMed ID: 15613451
    [Abstract] [Full Text] [Related]

  • 12. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P.
    Clin Cancer Res; 1995 Feb 02; 1(2):189-98. PubMed ID: 9815973
    [Abstract] [Full Text] [Related]

  • 13. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M.
    Cancer J Sci Am; 1999 Feb 02; 5(2):101-11. PubMed ID: 10198732
    [Abstract] [Full Text] [Related]

  • 14. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.
    Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, Lausi P, Novello S, Borasio P, Scagliotti GV.
    J Clin Oncol; 2006 Oct 20; 24(30):4818-24. PubMed ID: 17050866
    [Abstract] [Full Text] [Related]

  • 15. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases.
    Bellahcène A, Castronovo V.
    Bull Cancer; 1997 Jan 20; 84(1):17-24. PubMed ID: 9180854
    [Abstract] [Full Text] [Related]

  • 16. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M, Roagna R, Ponzone R, Biglia N, Sgro L, Perona M, Sismondi P.
    Anticancer Res; 1996 Jan 20; 16(2):875-81. PubMed ID: 8687144
    [Abstract] [Full Text] [Related]

  • 17. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
    Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G.
    N Engl J Med; 1998 Aug 06; 339(6):357-63. PubMed ID: 9691101
    [Abstract] [Full Text] [Related]

  • 18. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J, Kruszewski WJ, Sliwińska M, Kruszewska E, Hajdukiewicz W, Sliwiński W, Rolka-Stempniewicz G, Góralczyk M, Leśniewski-Kmak K.
    Przegl Lek; 2001 Aug 06; 58(6):498-503. PubMed ID: 11816740
    [Abstract] [Full Text] [Related]

  • 19. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A, Talieri M, Ardavanis A, Courtis N, Dimitriadis E, Yotis J, Tsiapalis CM, Trangas T.
    Cancer Res; 2000 Oct 01; 60(19):5427-33. PubMed ID: 11034084
    [Abstract] [Full Text] [Related]

  • 20. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W.
    Cancer; 2007 May 15; 109(10):1933-9. PubMed ID: 17407159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.